Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
11 evidence topics · 23 sources
Summary
- All patients treated for mCRPC eventually progress. The EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, citing cross-resistance that it extends from abiraterone to apalutamide and darolutamide.
- Activity of a second ARPI is limited. In a randomized crossover trial, PSA responses to second-line therapy occurred in 26 of 73 participants (36%) receiving enzalutamide and 3 of 75 (4%) receiving abiraterone. In a single-arm study of enzalutamide after at least 24 weeks of abiraterone, median radiographic progression-free survival (rPFS) was 8.1 months and the unconfirmed PSA response rate was 27% (48 of 181). In PLATO, adding abiraterone after PSA progression on enzalutamide did not prolong progression-free survival (5.7 vs 5.6 months; HR, 0.83; 95% CI, 0.61 to 1.12).
- In the control arms of randomized trials, median rPFS with a second ARPI was 3.7 months in CARD (after docetaxel), 3.6 months in PROfound cohort A (homologous recombination repair gene alterations), 4.5 months in the TRITON3 BRCA subgroup, and 5.59 months in PSMAfore (taxane-naive, third data cut-off), where 17% had a confirmed PSA decline of at least 50%. These figures are cross-trial. The PSMAfore investigators stated that a change in ARPI “has lesser clinical efficacy than taxanes”.
- Second ARPIs are nonetheless common in practice. In Medicare claims, novel hormonal therapy followed by a different novel hormonal therapy was the most common first- to second-line sequence (33%), only 28% of men starting first-line novel hormonal therapy later received a different class, and 22% received no life-prolonging therapy after mCRPC diagnosis.
- Taxane chemotherapy carries toxicity: the cabazitaxel label reports serious adverse reactions in 39% of recipients and neutropenic deaths, and in CARD treatment discontinuations for adverse reactions occurred in 20% of cabazitaxel recipients and 8% of those receiving abiraterone or enzalutamide. In TROPIC, grade 3 or higher neutropenia occurred in 82% of cabazitaxel recipients.
- PSMA-targeted radioligand therapy requires PSMA-positive disease on PET imaging and delivery by providers licensed to handle radiopharmaceuticals; in VISION, 126 screened participants (12.6%) did not meet PSMA imaging criteria. In PSMAfore, median overall survival was 24.5 months with lutetium Lu 177 vipivotide tetraxetan and 23.1 months with a change in ARPI (HR, 0.91; 95% CI, 0.72 to 1.14); the publication reported crossover in 134 of 234 participants (57%) randomized to ARPI change, which “may have confounded” the overall survival analysis, and the label reports crossover in 141 participants (60%).
- Biomarker-directed therapies apply to subsets. Alterations in BRCA2, BRCA1, or ATM were found in 29 of 150 metastatic biopsies (19.3%), rucaparib is labeled only for BRCA-mutated disease, and in the TRITON3 ATM subgroup the rPFS hazard ratio was 0.95 (95% CI, 0.59 to 1.52). First-line PARP inhibitor combinations are recommended only for patients who did not previously receive an ARPI, and the olaparib-abiraterone trial excluded prior abiraterone. Microsatellite instability-high or mismatch repair-deficient disease was found in 32 of 1033 patients (3.1%); pembrolizumab produced a response in 1 of 8 patients with prostate cancer in the tumor-agnostic label, and objective response rates of 5% and 3% in PD-L1-positive and PD-L1-negative cohorts after docetaxel and endocrine therapy.
- Other options have restricted populations: radium-223 is labeled for symptomatic bone metastases without known visceral disease, is not recommended with abiraterone plus prednisone because of more fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%), and caused bone marrow failure or ongoing pancytopenia in 2% of recipients. The sipuleucel-T trial excluded visceral metastases and moderate to severe cancer pain; each of its 3 doses requires leukapheresis, and it did not significantly prolong time to disease progression in any phase 3 study. Bisphosphonates have shown no survival benefit in any prospective trial, and overall survival was similar with denosumab and zoledronic acid.
Progression on available treatments
Cross-resistance between androgen receptor pathway inhibitors
Radiographic progression-free survival with a change in ARPI
“A change in ARPI has lesser clinical efficacy than taxanes,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“median rPFS in the ARPI change group was 5·59 months at third data cut-off” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Use of sequential ARPI therapy in place of chemotherapy
“However, real-world data indicates that many patients do not receive taxane-based chemotherapy after progression on a first ARPI and instead switch to a second ARPI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Toxicity of taxane chemotherapy after ARPI
Eligibility and delivery requirements for PSMA-targeted radioligand therapy
“The eligibility criteria for PSMA imaging were not met in 126 patients (12.6%; those with no PSMA-positive lesions or ≥1 exclusionary PSMA-negative lesion) and were met in 869 patients (86.6%; those with ≥1 PSMA-positive lesion and no exclusionary PSMA-negative lesions);” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival with radioligand therapy before taxane chemotherapy
Eligibility for homologous recombination repair-directed therapy
Eligibility for checkpoint inhibitor therapy
Undertreatment in routine practice
“22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data highlight the dramatic undertreatment that occurs for mCRPC patients, particularly for therapies beyond NHTs as well as the common use of sequential NHTs in real-world data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote